Format

Send to

Choose Destination
Sci Rep. 2016 May 5;6:25344. doi: 10.1038/srep25344.

Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models.

Author information

1
Department of Clinical Neurosciences, UCL Institute of Neurology, University College London, UK.
2
Department of Neurology, Shuang Ho Hospital, Taipei Medical University Taiwan.

Abstract

Meclizine is a well-tolerated drug routinely used as an anti-histamine agent in the management of disequilibrium. Recently, meclizine has been assessed for its neuroprotective properties in ischemic stroke and Huntington disease models. We found that meclizine protected against 6-hydroxydopamine-induced apoptosis and cell death in both SH-SY5Y cells and rat primary cortical cultures. Meclizine increases the level of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), which activates phosphofructokinase, a rate-determining enzyme of glycolysis. This protection is therefore mediated by meclizine's ability to enhance glycolysis and increase mitochondrial hyperpolarization. Meclizine represents an interesting candidate for further investigation to re-purpose for its potential to be neuroprotective in Parkinson disease.

PMID:
27145922
PMCID:
PMC4857109
DOI:
10.1038/srep25344
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center